Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 15/20 | 0.55 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775069 | 0.90 | LRRK2 (0.43) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL13006073 | 0.80 | LRRK2 (0.59) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL3774947 | 0.80 | LRRK2 (0.59) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL27848195 | 0.78 | LRRK2 (0.57) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL27848191 | 0.78 | LRRK2 (0.57) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL10224702 | 0.77 | LRRK2 (0.75) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL13834209 | 0.77 | LRRK2 (0.75) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL3774839 | 0.77 | KDM4E (0.41) | LRRK2ALDH1A1RECQL | |
| SCHEMBL3775072 | 0.70 | MAPT (0.50) | LRRK2KDM5AKDM4CKDM5BPROKR1 | |
| SCHEMBL13006068 | 0.70 | MAPT (0.50) | LRRK2KDM5AKDM4CKDM5BPROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2309/4885KDM5A 4287/4885KDM4C 2730/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2208/4885KDM5A 4306/4885KDM4C 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.